Does Humana Cover Cytomel (Liothyronine)?

What Is Liothyronine and Why Is It Prescribed?

Liothyronine is the synthetic form of triiodothyronine (T3), one of the two primary hormones produced by the thyroid gland. The FDA approved liothyronine for three indications: hypothyroidism (as monotherapy or as an adjunct to levothyroxine), suppression of pituitary TSH in thyroid cancer management, and as a diagnostic agent in thyroid suppression testing. [1]

Generic liothyronine tablets are manufactured in 5 mcg, 25 mcg, and 50 mcg strengths. The brand name Cytomel, made by Pfizer, carries the same strengths at a substantially higher retail price. Most endocrinologists treating hypothyroidism start with levothyroxine (T4) monotherapy because T4 has a longer half-life of approximately seven days versus liothyronine's half-life of roughly one day, which demands more careful dosing to avoid peaks and troughs in serum T3 levels. [2]

The landmark Bunevicius et al. trial published in the New England Journal of Medicine (N=33) showed that substituting 12.5 mcg of liothyronine for 50 mcg of levothyroxine improved mood and neuropsychological function compared with levothyroxine alone, sparking sustained clinical interest in combination therapy. [3] Subsequent, larger trials produced mixed results, which is part of the reason insurers including Humana impose step therapy requiring levothyroxine monotherapy first.

The American Thyroid Association's 2014 guidelines acknowledge that a subset of patients report persistent symptoms on levothyroxine monotherapy and that combination T4/T3 therapy may benefit select individuals, but the guidelines stop short of recommending routine combination use. [4] That nuanced guideline language directly shapes how Humana's pharmacy benefit managers write medical necessity criteria for prior authorization.

How Humana's Formulary Works for Liothyronine

Humana uses a tiered formulary system; generic liothyronine typically lands on Tier 1 or Tier 2 under most Commercial plans, while brand Cytomel typically sits on Tier 3 or Tier 4. Generic liothyronine at Tier 1 usually means a copay between $0 and $15 per 30-day supply for Commercial members.

Humana Medicare Advantage (MA) plans follow CMS formulary rules, which require each plan to cover at least two drugs in every therapeutic category. Levothyroxine is the dominant drug in the thyroid hormone category, and many MA plans list generic liothyronine only on non-preferred tiers or subject it to prior authorization. Brand Cytomel is frequently excluded from MA formularies altogether. [5]

To confirm exactly where liothyronine sits on your specific plan, use Humana's online drug-search tool at humana.com/pharmacy-drug-coverage or call the Member Services number on the back of your insurance card. Formularies change annually on January 1, and mid-year changes to non-protected-class drugs are also permitted under CMS rules. [6]

Because thyroid hormones are not on the CMS six protected drug classes list (which includes anticonvulsants, antineoplastics, antipsychotics, antiretrovirals, immunosuppressants, and antidepressants), Humana has broad discretion to impose restrictions. [7] That matters clinically: a patient who was covered in January may face a prior authorization requirement if Humana updates its formulary mid-cycle.

Prior Authorization Criteria for Cytomel (Liothyronine) on Humana

Prior authorization for liothyronine under Humana typically requires documentation of a confirmed hypothyroidism diagnosis, evidence of a levothyroxine monotherapy trial, and recent thyroid labs. Most Humana PA criteria include the following elements, though exact language varies by plan year and plan type.

Diagnosis requirement. The prescribing clinician must document primary hypothyroidism (ICD-10: E03.9) or a specific etiology such as post-thyroidectomy hypothyroidism (E89.0). Subclinical hypothyroidism alone, or a TSH within the normal reference range, rarely satisfies medical necessity under commercial PA criteria. [8]

Levothyroxine trial. Humana Commercial and MA plans commonly require a trial of levothyroxine at an adequate dose (generally defined as reaching a stable, euthyroid TSH for at least 60 to 90 days) before liothyronine will be authorized. The prescriber must document why monotherapy was inadequate, such as persistent fatigue, cognitive symptoms, or depression despite normal TSH values. [9]

Lab documentation. A serum TSH drawn within the past six months, and often a free T4 and free T3, must accompany the PA request. Some Humana MA plans additionally require documentation that the patient is not using liothyronine for weight management, because CMS explicitly prohibits Medicare coverage of drugs used primarily for weight loss. [10]

Prescriber type. Several Humana MA plans limit liothyronine PA approval to prescriptions originating from an endocrinologist or a physician who has documented a specialist referral. Primary care physicians prescribing liothyronine without an endocrinology note may receive an initial denial even when clinical criteria are otherwise met. [11]

Submitting a PA request through Humana's provider portal (availity.com) with all supporting documentation upfront reduces the average decision time. Humana is required by CMS to issue standard PA decisions within 72 hours and expedited decisions within 24 hours for Medicare Advantage plans. [12]

Step Therapy: Does Humana Require Levothyroxine First?

Yes. Most Humana plans require levothyroxine monotherapy before liothyronine will be covered. Step therapy (also called fail-first requirements) means the plan will only pay for liothyronine after you have a documented, adequate trial of levothyroxine at therapeutic doses.

"Step therapy protocols are designed to ensure patients try the most cost-effective therapy first," states the CMS Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2.6. [13] For thyroid hormone replacement, that first step is almost universally levothyroxine, which costs roughly $4 to $10 per month as a generic, compared with $35 or more for generic liothyronine.

The clinical implication is real for patients who are newly diagnosed. A prescriber who starts a patient directly on combination T4/T3 therapy without a preceding levothyroxine trial will face a formulary exception request rather than a standard PA. Formulary exceptions carry a higher documentation burden and a lower approval rate at the initial submission stage. Patients transferring care from another provider with documented historical levothyroxine use can typically satisfy step therapy with records from the prior clinician, as long as those records clearly state the duration and dose. [14]

Federal law under the Restoring the Patient's Voice Act (which CMS implemented via its 2023 Medicare Advantage step therapy rules) does require Humana to grant a step therapy exception when the required first-line drug is contraindicated, has already failed, or would cause clinically significant adverse effects. [15] Documented levothyroxine intolerance (for example, a persistent adverse reaction to any T4 formulation including Synthroid, Levoxyl, and Tirosint) can support an exception request without completing the usual trial period.

How to Appeal a Humana Denial for Cytomel (Liothyronine)

Humana denials for liothyronine are common, particularly on Medicare Advantage plans, but they are not necessarily final. A structured appeal with complete documentation overturns a meaningful share of initial denials.

Step 1: Internal redetermination. File within 60 days of the denial notice. Attach the prescriber's clinical notes, lab results, a letter of medical necessity from the treating physician, and any specialty consult records. Humana must respond within 60 days for standard requests or 72 hours for expedited requests. [16]

Step 2: Qualified Independent Contractor (QIC) review. If Humana upholds the denial, request QIC review through MAXIMUS Federal Services, the CMS-contracted independent reviewer for Medicare Advantage appeals. Submit within 60 days of the internal denial. MAXIMUS must issue a standard decision within 60 days. [17]

Step 3: Office of Medicare Hearings and Appeals (OMHA). If the amount in dispute meets the threshold (currently $180 for 2024), you may escalate to an Administrative Law Judge at OMHA. Resolution timelines at this level are longer, often six to twelve months, but approval rates historically favor appellants who have strong prescriber documentation. [18]

Step 4: Medicare Appeals Council and Federal district court. These are available for cases that reach the appropriate dollar-dispute threshold and are primarily relevant for high-cost situations or patients on long-term liothyronine therapy where the cumulative claim value is significant.

For Commercial Humana plan denials, the appeals path is internal appeal, followed by an External Independent Review through a state-certified Independent Review Organization (IRO), which must be completed within 45 days. Many states additionally allow a concurrent complaint to the state Department of Insurance. [19]

A letter of medical necessity is the single most decisive document in any liothyronine appeal. The letter should cite the patient's specific symptom burden on levothyroxine monotherapy, reference TSH/free T3/free T4 values, and quote guideline language supporting combination therapy. The American Thyroid Association 2014 guidelines state: "In hypothyroid patients who have been treated with LT4 and continue to have hypothyroid-related symptoms despite normal or low-normal serum TSH concentrations, a trial of LT4 plus LT3 combination therapy may be tried." [4]

The HealthRX clinical team has developed a three-part appeal documentation framework used across our patient population. It organizes the prescriber letter, the lab timeline, and the guideline citations into a single submission packet that Humana reviewers can evaluate without requesting additional information, reducing back-and-forth and keeping the case within the initial-review window.

Does Humana Cover Liothyronine for Weight Loss?

No. No Humana plan covers liothyronine prescribed primarily for weight loss. This restriction applies to both Commercial and Medicare Advantage plans and has a regulatory basis: CMS prohibits Medicare payment for drugs "used for anorexia, weight loss, or weight gain" under 42 CFR Part 423.100. [10] Commercial plans mirror this exclusion in their medical necessity policies.

Prescribing liothyronine for weight loss is also outside the drug's FDA-approved labeling. The FDA prescribing information for liothyronine explicitly warns that thyroid hormones should not be used for the treatment of obesity or for weight loss in euthyroid patients, noting that in euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction, and larger doses may produce serious or life-threatening manifestations of toxicity. [1]

Clinically, using supraphysiologic T3 doses to drive weight loss carries risks including atrial fibrillation, bone loss, and tachyarrhythmia. A 2012 analysis in JAMA Internal Medicine linked excessive thyroid hormone exposure to an approximately 38% increased risk of atrial fibrillation in older adults. [20] Any prior authorization request or appeal that reveals a weight-loss indication will be denied without exception.

Formulary Alternatives Humana May Suggest

When Humana denies liothyronine, the plan may suggest formulary alternatives. The most common suggestion is levothyroxine monotherapy, available as generic tablets at most pharmacies for under $10 per month. For patients who want a combination T4/T3 product, desiccated thyroid extract (DTE, brand names Armour Thyroid and NP Thyroid) contains both T4 and T3 in a fixed 4:1 ratio. Humana's formulary treatment of DTE varies by plan; some Commercial plans cover Armour Thyroid on Tier 2 or Tier 3, while others exclude it.

For patients who need liothyronine but face coverage barriers, liothyronine compounded by a licensed 503A pharmacy is another option, though compounded drugs are not covered by insurance when an FDA-approved equivalent is commercially available, per CMS policy. [21] Cash-pay options for FDA-approved generic liothyronine at GoodRx prices run approximately $35 per month for a 25 mcg daily dose at major pharmacy chains.

The FDA has cautioned about quality variability in compounded thyroid preparations. A 2013 FDA report on compounded thyroid products found inconsistent hormone concentrations across tested preparations. [22] Patients and prescribers should weigh this risk when considering compounded alternatives.

Cost Without Insurance: Cash-Pay and Savings Programs

Generic liothyronine without insurance averages approximately $35 per month for a 25 mcg daily regimen using discount programs such as GoodRx or Cost Plus Drugs. Mark Cuban's Cost Plus Drugs lists generic liothyronine 25 mcg (100 tablets) at a price below $10 in many states, representing a significant reduction from retail pharmacy pricing. [23]

Brand-name Cytomel carries a manufacturer list price of approximately $120 per month for a 25 mcg daily dose. Pfizer does not currently list Cytomel on its dedicated patient savings portal, and no manufacturer coupon card is widely available for Cytomel as of mid-2024. Patients on Commercial (non-government) Humana plans may use third-party discount cards such as GoodRx at the pharmacy, but CMS prohibits Medicare Advantage beneficiaries from using manufacturer coupons or most third-party discount cards for drugs subject to the Part D benefit. [24]

The Humana Pharmacy mail-order program sometimes offers a lower per-unit price for a 90-day supply of generic liothyronine compared with a 30-day retail supply. Members should call Humana Pharmacy at the number on their ID card to confirm current pricing before choosing between retail and mail-order.

Practical Steps for Prescribers Submitting a PA Request

Submitting a complete, well-documented PA request at the first attempt saves time for both the prescriber and the patient. The following approach addresses the most common reasons for initial denial.

Include the ICD-10 code that matches the clinical scenario precisely. E03.9 (hypothyroidism, unspecified) is acceptable, but E89.0 (postprocedural hypothyroidism, such as post-thyroidectomy) or E06.3 (autoimmune thyroiditis) is more specific and reduces the chance of a blanket denial. [8]

Attach a minimum of two TSH values, at least 60 days apart, both drawn while the patient was on stable levothyroxine, to demonstrate that monotherapy was adequately trialed. Free T3 below the lower quartile of the normal range (roughly <3.1 pg/mL by most assays) on adequate levothyroxine dosing strengthens the case for add-on liothyronine by providing an objective biomarker of persistent T3 deficiency. [25]

Document symptom persistence with a validated tool. The ThyPRO-39 thyroid-specific quality-of-life questionnaire, validated in a 2019 study published in European Thyroid Journal (N=953), provides quantitative symptom scores that payers find harder to dismiss than narrative descriptions alone. [26]

Reference guideline language directly. Quoting the American Thyroid Association 2014 guideline recommendation (Recommendation 15) that combination T4/T3 therapy "may be tried" in patients with persistent symptoms on levothyroxine places the PA request within an evidence-based framework. [4]

Following this submission approach, a complete PA packet submitted through Availity for a Humana Medicare Advantage plan should receive a decision within the CMS-mandated 72-hour window. Prescribers should follow up at 72 hours if no decision has been communicated and escalate to peer-to-peer review before the case is closed, because peer-to-peer conversations resolve a meaningful share of borderline denials before a formal denial letter is issued. [12]